Company: APXIF
Filing Date: 2025-06-11
Form Type: 10-Q
Source: 0001213900-25-053185
Chunk: 121

Company: APx Acquisition Corp. I
Filing Date: 2025-06-11
Form: 10-Q
Item: Part I, Item 8
Chunk 121
---
ebtedness (subject to certain exceptions) owed by OmnigenicsAI or any Subsidiary of OmnigenicsAI to Parent or
any shareholder of Parent, shall be cancelled and extinguished. The Indebtedness described in this paragraph that is not required to be
canceled and extinguished at Closing shall have their maturity date extended to three years following the Closing Date.

On the Closing Date at
the Merger Effective Time, pursuant to the Business Combination Agreement, Merger Sub will merge with and into the Company (with the Company
being the surviving company and becoming a direct wholly-owned subsidiary of OmnigenicsAI) (the “Merger”) and, as a result
of the Merger, (a) each ordinary share of the Company (“SPAC Ordinary Share”) outstanding will be exchanged for the right
to receive one ordinary share of OmnigenicsAI, nominal value $0.0001 per share (“Company Share”), (b) all warrants to purchase
SPAC Ordinary Shares (“SPAC Warrants”) will become warrants of OmnigenicsAI (“Company Warrants”) exercisable for
Company Shares, on substantially the same terms as the SPAC Warrants and (c) OmnigenicsAI shall enter into an Assignment, Assumption
and Amendment Agreement with the Company and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent,
to amend and assume the Company’s obligations under the existing Warrant Agreement, dated December 6, 2021, to give effect
to the conversion of SPAC Warrants to Company Warrants.

Conditions to Each Party’s Obligations

The obligations of the
parties to consummate the Proposed Business Combination are subject to the satisfaction or waiver of customary closing conditions at or
prior to the Closing, including (a) approval by the Company’s shareholders; (b) effectiveness of the registration statement
on Form F-4 relating to Company Shares and Company Warrants to be issued in the Merger; (c) Nasdaq listing approval of
the Company Shares and Company Warrants; (d) absence of any law, rule, regulation, judgment, decree, executive order or award which
is then in effect and has the effect of making the Proposed Business Combination illegal or otherwise prohibiting consummation of the
Proposed Business Combination; and I the Company or OmnigenicsAI having at least $5,000,001 of net tangible assets